GlassScriptPhysician profile
Gregory Doy Snodgrass
NPI 1043270044
$6,486.08
in general payments reported to CMS, 2019-2025
24 companies · $993 in 2025
The $993 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,812 · 2020: $655 · 2021: $578 · 2022: $849 · 2023: $782 · 2024: $817 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198 · Travel and Lodging: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.09 |
| Travel and Lodging | $393.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,306.86 | 2019-2025 | Clareon, Ngenuity, Clareon Panoptix Pro |
| Kala Pharmaceuticals, INC. | $501.55 | 2020-2022 | |
| Abbvie INC. | $335.47 | 2022-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $248.99 | 2019-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $147.41 | 2019-2021 | |
| New World Medical,INC. | $138.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.92 | 2019-2021 | |
| Spark Therapeutics, INC. | $85.82 | 2019 | |
| Allergan, INC. | $79.69 | 2020-2022 | |
| Ocular Therapeutix, INC. | $66.04 | 2023-2025 | Dextenza |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Sight Sciences, INC. | $60.34 | 2019-2024 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $55.06 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $54.27 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $46.62 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $39.40 | 2021 | |
| Omeros Corporation | $28.47 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $23.33 | 2023 | Acuvue |
| Oyster Point Pharma, INC. | $22.64 | 2022 | |
| Rxsight INC | $20.49 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Harrow Eye, LLC | $20.10 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $17.76 | 2019 | |
| Biotissue Holdings INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Snodgrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.